Simris Alg AB Class B (SIMRIS.B) AI Stock Analysis

• Market Cap: kr128.23M
• Dividend Yield: N/A
• Average Volume (3M): 223.88K
• Price to Earnings (P/E): ―
• Beta (1Y): 0.45
• Revenue Growth: -49.72%
• EPS Growth: 36.20%
• Country: SE
• Employees: 7
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): >-0.01
• Shares Outstanding: 1,349,793,200
• 10 Day Avg. Volume: 120,731
• 30 Day Avg. Volume: 223,875
• PEG Ratio: 0.02
• Price to Book (P/B): -76.69
• Price to Sales (P/S): 22.32
• P/FCF Ratio: 0.00
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 43 Neutral
• Price Target: kr0.09 ▲(130.00% Upside)
• Action: Upgraded Date: 03/02/26
• Date: Action: Upgraded 03/02/26

The score is weighed down primarily by very weak financial performance (shrinking revenue, heavy losses, ongoing cash burn, and deteriorating balance sheet with negative equity and higher debt). Technicals are mixed and only mildly supportive, while valuation offers limited comfort due to negative earnings and no dividend yield.

Positive Factors

Vertical integration

Owning cultivation through commercialization gives durable operational control over feedstock, quality and formulation. That vertical setup can protect margins, secure supply vs commodity shocks, and enable product differentiation if volumes and efficiencies scale.

Niche sustainable omega-3 product

Positioning in algae-derived omega-3s places the company in a specialized, sustainability-focused segment of nutraceuticals. Structurally, demand for non-fish omega-3 alternatives supports long-term market opportunities and potential premium positioning for differentiated ingredients.

Prior positive gross profit period

Historic positive gross profit in 2023–2024 demonstrates underlying unit economics can be positive under certain conditions. This implies that with stabilized costs, pricing or scale the business model can return to positive margins over the medium term.

Negative Factors

Shrinking revenue

Steep, persistent revenue decline erodes scale benefits and makes fixed-cost absorption harder. Lower top-line undermines margin recovery, reduces bargaining power with customers and suppliers, and lengthens the path to sustainable profitability absent a clear revenue turnaround.

Persistent negative cash flow

Consistent operating cash burn signals the core business does not self-fund growth and operations. Over months this forces reliance on external financing, increasing dilution or debt, compressing runway, and limiting the firm’s ability to invest in production scale or commercial expansion.

Deteriorated balance sheet & rising debt

Negative equity and a sharp increase in debt materially reduce financial flexibility. Higher leverage raises refinancing and solvency risk, may trigger covenants or higher funding costs, and constrains strategic options for partnerships, capital investment, or recovery plans.

Simris Alg AB Class B Business Overview & Revenue Model

Company Description

Simris Alg AB Class B (SIMRIS.B) is a Swedish biotechnology company focused on the sustainable production of high-value products derived from microalgae. Operating primarily in the sectors of food, health, and nutrition, Simris Alg specializes in cultivating various species of algae to create ingredients such as omega-3 fatty acids, proteins, and other bioactive compounds. The company aims to provide natural alternatives to commercially available products, promoting health and wellness while minimizing environmental impact.

How the Company Makes Money

Simris Alg generates revenue primarily through the sale of its algae-derived products, which include omega-3 supplements and other nutritional ingredients. The company has developed a range of branded products aimed at both consumers and health-focused businesses. Key revenue streams include direct sales to consumers via e-commerce platforms, partnerships with health and wellness retailers, and collaborations with food and supplement manufacturers seeking natural ingredients. Additionally, strategic partnerships with research institutions and collaborations with other companies in the biotechnology space enhance its R&D capabilities and market reach, contributing positively to its financial performance.

Simris Alg AB Class B Financial Statement Overview

Summary

Financials indicate very high risk: revenues are small and declining sharply, losses are persistent and deep, operating cash flow remains materially negative, and 2025 shows a step-change in financial stress with equity turning slightly negative alongside a sharp rise in debt.

Income Statement

The income statement remains very weak. Revenue is small and declining (down ~34% in 2024 and ~37% in 2025), while profitability is deeply negative with recurring large operating losses and net losses each year. Gross profit was positive in 2023–2024 but swung sharply negative in 2025, indicating deteriorating unit economics and limited operating leverage despite years of operations.

Balance Sheet

The balance sheet has deteriorated materially. Equity fell from positive levels in prior years to slightly negative in 2025, which reduces financial flexibility and signals accumulated losses have eroded the capital base. At the same time, total debt jumped dramatically in 2025, creating a highly leveraged profile versus an asset base that has not translated into earnings, raising refinancing and solvency risk.

Cash Flow

Cash flow quality is weak and consistently negative. Operating cash flow has been materially negative every year shown, indicating the core business is not self-funding. Free cash flow is also negative when reported (2020–2024) and the 2025 free cash flow value appears as zero, suggesting either a reporting gap or a sharp change that is not corroborated by still-negative operating cash flow; overall, liquidity burn remains a key concern.

Breakdown	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	1.61M	2.89M	4.35M	4.08M	6.14M
Gross Profit	-31.34M	1.22M	2.01M	-742.00K	-2.07M
EBITDA	-17.32M	-17.59M	-22.36M	-18.00M	-24.81M
Net Income	-26.81M	-34.60M	-37.30M	-24.42M	-28.36M
Balance Sheet
Total Assets	148.38M	157.06M	174.55M	185.71M	29.20M
Cash, Cash Equivalents and Short-Term Investments	1.47M	1.95M	5.67M	3.99M	961.00K
Total Debt	87.68M	2.04M	2.67M	2.13M	3.13M
Total Liabilities	148.85M	151.42M	148.94M	162.68M	10.98M
Stockholders Equity	-470.00K	5.64M	25.61M	23.03M	18.22M
Cash Flow
Free Cash Flow	0.00	-18.63M	-37.96M	-40.57M	-18.39M
Operating Cash Flow	-16.05M	-18.02M	-36.35M	-18.19M	-18.14M
Investing Cash Flow	-224.00K	-613.00K	-1.61M	-22.38M	-253.00K
Financing Cash Flow	15.79M	14.91M	39.63M	43.60M	2.84M

Simris Alg AB Class B Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 0.04
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SE:SIMRIS.B, the sentiment is Positive. The current price of 0.04 is below the 20-day moving average (MA) of 0.11, below the 50-day MA of 0.08, and below the 200-day MA of 0.12, indicating a neutral trend. The MACD of >-0.01 indicates Positive momentum. The RSI at 50.50 is Neutral, neither overbought nor oversold. The STOCH value of 34.27 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for SE:SIMRIS.B.

Simris Alg AB Class B Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
ONCOZ	47 Neutral	kr77.91M	-5.12	-78.79%	―	―	20.55%
EXPRS2	45 Neutral	kr53.73M	-1.11	-88.65%	―	8.46%	11.73%
PILA	44 Neutral	kr50.50M	-2.38	-601.02%	―	―	―
SIMRIS.B	43 Neutral	kr128.23M	-2.13	―	―	-49.72%	36.20%
MODTX	43 Neutral	kr35.27M	-1.33	-166.94%	―	―	-19.35%
LPGO	41 Neutral	kr3.03M	-0.08	-213.85%	―	―	―